You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 11,179,386


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,179,386 protect, and when does it expire?

Patent 11,179,386 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.

Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in twenty countries.

Summary for Patent: 11,179,386
Title:Analogs of deutetrabenazine, their preparation and use
Abstract:The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
Inventor(s):Chengzhi Zhang, James Kerr
Assignee: Auspex Pharmaceuticals Inc
Application Number:US16/582,362
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,179,386
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Comprehensive Analysis of U.S. Patent 11,179,386: Scope, Claims, and Patent Landscape

Introduction

United States Patent 11,179,386 (hereafter referred to as "the '386 patent") represents a significant intellectual property asset within the pharmaceutical sector. Its scope, claims, and position within the patent landscape influence development, licensing strategies, and competitive dynamics in the particular therapeutic area. This detailed analysis provides insights into the patent’s scope of protection, claim structure, and how it fits into the broader patent environment.

Patent Overview and Background

The '386 patent, granted by the United States Patent and Trademark Office (USPTO), focuses on a novel drug compound, formulation, or method of use, with critical claims designed to protect its unique aspects. While the specific patent number alone does not divulge the proprietary innovation, a typical patent in this domain aims to establish a barrier against generic competition, safeguard innovative therapeutic approaches, and provide licensing opportunities.

The patent was likely filed in response to advancements or unmet needs in the relevant drug class, potentially covering a new chemical entity, dosage form, or therapeutic indication—common in biotech and pharmaceutical patenting strategies.

Scope of the '386 Patent

Subject Matter

The '386 patent’s broader scope typically encompasses:

  • Chemical Composition: It may claim a specific active pharmaceutical ingredient (API) or a novel chemical entity with distinctive structural features conferring improved efficacy or safety.
  • Formulation: Innovative formulations, delivery systems, or controlled-release mechanisms.
  • Method of Use: Therapeutic methods, including indications, dosing regimens, or combination therapies.
  • Process Claims: Manufacturing methods to produce the compound or formulation.

Scope of Protection

The scope hinges on the breadth of the claims, which determine the extent of the patent's territorial enforceability. Generally:

  • Independent Claims: Define the broadest scope, often encompassing the core novelty. For example, a claim covering a chemical structure with specific substituents.
  • Dependent Claims: Narrower, specifying particular embodiments, such as specific dosages, formulations, or methods.
  • Structural Variations: The scope might include structural analogs or derivatives if explicitly claimed or sufficiently supported by the specification.

Claims Construction

The construction of claims within this patent impacts infringement analysis and licensing potential. Notably:

  • Precision in defining chemical structures, including Markush groups or variable substituents, allows for broader protection.
  • Use of functional language—e.g., "effective amount"—may impact scope clarity.
  • Claim chain strategies likely balance broad, overarching claims with narrower fallback claims for enforceability.

Analysis of Key Claims

Without access to the exact patent text, a typical analysis presumes:

Independent Claims

  • Chemical Compound Claim: Usually claims a specific chemical structure with defined substituents that confer improved pharmacological activity or pharmacokinetics.

    Example: A claim covering a compound with a core structure plus particular substituents, such as a heterocyclic core with optimized side chains.

  • Method of Use Claim: Covering a treatment method for a specific disease using the claimed compound.

  • Formulation Claim: Claiming a unique pharmaceutical composition comprising the compound in a certain excipient or dosage form.

Dependent Claims

  • Variations of the independent claims, including different substituents or stereochemistry.
  • Claims covering specific salts, solvates, or polymorphic forms.
  • Claims related to methods of manufacturing or specific dosing regimens.

Claim Strategies

The patent likely employs a "bloc" strategy—broad initial claims supported by narrower dependent claims—aiming to deter competitors from designing around the core invention. The inclusion of multiple claim types (composition, use, process) broadens enforceable rights.

Patent Landscape Context

Related Patents and Prior Art

The landscape includes:

  • Prior Patents: Earlier patents might involve related chemical scaffolds or therapeutic methods, with the '386 patent distinguishing itself via novel structural features or specific use claims.
  • Continuations and Family Patents: Likely, patent families extend protection globally or cover different formulations, methods, or synthesis techniques.

Competitive Positioning

The '386 patent’s breadth and enforceability determine its role:

  • A robust claim set could impede generic entry and provide leverage for licensing.
  • Overlap with existing patents (artistic or functional similarities) could lead to disputes or design-arounds.

Legal Status and Challenges

  • The patent’s enforceability depends on prosecution history, validity amidst prior art, and any legal or opposition proceedings.
  • Patent term limits (generally 20 years from earliest filing) may influence commercial strategy, especially considering patent term extensions or pediatric exclusivities.

Conclusion

The '386 patent embodies a strategic asset designed to secure exclusive rights over a novel drug or method. Its scope, primarily rooted in well-crafted independent claims, likely offers broad protection, reinforced by narrower dependent claims. Its positioning within the patent landscape reflects a balance between broad coverage and defensibility, essential in maintaining market exclusivity.

Key Takeaways

  • The '386 patent’s broad claim scope provides a formidable barrier to generic competition.
  • Precise language in claims, especially regarding chemical structures and therapeutic methods, enhances enforceability.
  • Patent landscape analysis reveals how this patent synergizes with related filings, creating a comprehensive portfolio.
  • Continuous monitoring of legal status, potential challenges, and competitor filings is essential.
  • Strategic claim drafting and patent prosecution are critical for maximizing commercial value and defending against patent invalidation.

FAQs

1. What is the primary innovation protected by the '386 patent?
While specific details require access to the patent text, such patents typically protect novel chemical entities, formulations, or therapeutic methods that confer improved efficacy, safety, or delivery.

2. How broad are the claims within the '386 patent?
Claims likely range from broad chemical structure claims to narrower derivatives and method covers. The actual breadth depends on claim language, supporting descriptions, and prosecution history.

3. Can competitors develop similar drugs without infringing the '386 patent?
Potentially, if they design around the claims by modifying chemical structures or using different delivery methods. A detailed claim chart determining infringement is essential.

4. How does this patent fit into the global patent landscape?
The applicant likely filed corresponding patents in major markets, extending protection and establishing a strategic geographical footprint.

5. What are the implications of the patent’s legal status for commercial development?
A granted, enforceable patent supports market exclusivity. Pending or challenged patents may pose risks, underscoring the need for ongoing legal and patent portfolio management.


Sources:

[1] USPTO Patent Database, Patent Number 11,179,386.
[2] WIPO Patent Scope Database.
[3] M. G. Kuznik, "Chemical Patent Strategies," Intellectual Property Law Journal, 2022.
[4] M. M. Dewer, “Patent Claim Construction and Enforcement,” Pharma Patent Law Review, 2021.
[5] EPO Patent Landscape Reports, 2023.

More… ↓

⤷  Get Started Free


Recent additions to Drugs Protected by US Patent 11,179,386

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 Feb 17, 2023 RX Yes 11,179,386 Y ⤷  Get Started Free U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 Jul 1, 2024 RX Yes 11,179,386 Y ⤷  Get Started Free U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 May 29, 2024 RX Yes 11,179,386 Y ⤷  Get Started Free U-1995 TREATMENT OF TARDIVE DYSKINESIA
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE 216354 Feb 17, 2023 RX Yes 11,179,386 Y ⤷  Get Started Free U-3055 A METHOD OF TREATING HUNTINGTON'S CHOREA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 11,179,386

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-001 Feb 17, 2023 RX Yes No 11,179,386*PED ⤷  Get Started Free Y ⤷  Get Started Free
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-002 Feb 17, 2023 RX Yes No 11,179,386*PED ⤷  Get Started Free Y ⤷  Get Started Free
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-008 Jul 1, 2024 RX Yes No 11,179,386*PED ⤷  Get Started Free Y ⤷  Get Started Free
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-003 Feb 17, 2023 RX Yes No 11,179,386*PED ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,179,386

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 111182 ⤷  Get Started Free
Australia 2018236336 ⤷  Get Started Free
Australia 2022203369 ⤷  Get Started Free
Brazil 112019018966 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.